The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. About NVX-CoV2373.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. The award is funding the U.S.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Drug Discovery World

MAY 25, 2023

Using complex models of cancer for preclinical testing After a coffee break, Prof Sansom was back behind the podium talking about the MRC National Mouse Genetics Network. Advances like genetically engineered mouse models (GEMMs), patient-derived xenografts (PDXs) and organoids are allowing the integration of mouse models with human cohorts.

Research 52

Research Drugs In-Vitro Insulin 52

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. protein-based biologics) : are those which bind to specific components (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

MARCH 6, 2024

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. Despite the disappointing launch of Aduhelm and questions around Leqembi, companies like Eli Lilly are continuing to pursue their beta-amyloid monoclonal antibody therapies.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

The Pharma Data

OCTOBER 26, 2020

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. About AR-711.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Manufacturing 52

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

The Pharma Data

JANUARY 10, 2021

CERC-002 is a human anti-LIGHT monoclonal antibody. INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the Fc domain of the immunoglobulin IgG1. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Drug Discovery World

JULY 22, 2022

To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. NK and CAR-NK cells can mediate similar mechanisms of cytotoxicity through antibody-dependent cell cytotoxicity (ADCC) and act through the Fc? receptor 25. After earning a B.A.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

pharmaphorum

JANUARY 10, 2022

Molecular Partners’ drug is designed to block three areas of the receptor binding domains of the viral spike protein, potentially making it less vulnerable to escape mutations that can limit the effectiveness of single-target antibodies.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

JANUARY 24, 2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections. At Elasmogen we have been able to capture, using the latest protein and genetic engineering techniques, the immune system of 10,000 shark equivalents in a test-tube.

Antibody 52

Antibody Protein Research Genetic Engineering 52

Drug Discovery World

SEPTEMBER 28, 2022

“The astrocytes begin to secrete a protein that promotes inflammation called MCP-1, and in response to this, the cancer cells begin to express its receptors CCR2 and CCR4, which we suspected to be responsible for the destructive communication with the astrocytes.” . Spread of metastases delayed .

Research 52

Research Gene Editing Genetic Engineering Protein 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52